Imagion Biosystems Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume10.77 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive IBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Imagion Biosystems and its competitors with MarketBeat's FREE daily newsletter.

About Imagion Biosystems

Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Imagion Biosystems (ASX:IBX) Frequently Asked Questions

What stocks does MarketBeat like better than Imagion Biosystems?

Wall Street analysts have given Imagion Biosystems a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Imagion Biosystems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Imagion Biosystems' key executives?

Imagion Biosystems' management team includes the following people:
  • Mr. Robert Romeo Proulx, Exec. Chairman, Pres & CEO (Age 63, Pay $436.35k)
  • Mr. Geoff Hollis, CFO & Company Sec.
  • Dr. Marie Zhang, Vice-Pres of Research & Pre- Clinical Dev

Who are some of Imagion Biosystems' key competitors?

What other stocks do shareholders of Imagion Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Imagion Biosystems investors own include Arcadia Biosciences (RKDA), Schroders (PYX), Paradigm Biopharmaceuticals (PAR), Alibaba Group (BABA) and Amani Gold (ANL).

What is Imagion Biosystems' stock symbol?

Imagion Biosystems trades on the ASX under the ticker symbol "IBX."

How much money does Imagion Biosystems make?

Imagion Biosystems has a market capitalization of $0.00 and generates $3.17 million in revenue each year.

What is Imagion Biosystems' official website?

The official website for Imagion Biosystems is

How can I contact Imagion Biosystems?

The company can be reached via phone at 855-564-5264.

This page was last updated on 9/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.